Adults who have been diagnosed with chronic myeloid leukemia (CML) may benefit from Tasigna® (nilotinib). This medicine can help slow down the progression of the leukemia by blocking certain proteins in the body that the cancer cells need to grow and multiply.
Tasigna comes in the form of a capsule that is taken twice daily, with 12 hours between doses. Your specific dosage will depend on how you respond to the medicine, whether you are taking other medications, and other factors.
Before starting treatment with Tasigna, make sure to review the medication's safety information with your healthcare provider. For example, you may not be able to use this drug if you have an irregular heartbeat, heart disease, or a history of pancreatitis. Also, this drug may react with certain other medications.
(For more information on this medication, click Tasigna. This article offers a complete overview on this drug, including details on side effects, dosing guidelines, effectiveness, and more.)
Written by/reviewed by: Arthur Schoenstadt, MD
Last reviewed by: ArthurSchoenstadt, MD
List of references (click here):
Tasigna [package insert]. East Hanover, NJ: Novartis;2011 January.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 18, 2011.
National Library of Medicine (US). Hazardous Substances Data Bank (HSDB). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed October 12, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click